iCAD to Participate in Craig-Hallum’s 4th Annual Alpha Select Conference

  iCAD to Participate in Craig-Hallum’s 4th Annual Alpha Select Conference

4th Annual Craig-Hallum Alpha Select Conference

Business Wire

NASHUA, N.H. -- September 24, 2013

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image
analysis, workflow solutions and radiation therapy for the early
identification and treatment of cancer, today announced that Company
management will participate in Craig-Hallum’s 4^th Annual Alpha Select
Conference taking place on September 26, 2013 at the Convene Conference Center
in New York City. Ken Ferry, iCAD’s President and Chief Executive Officer,
will deliver a corporate overview at 3:45 p.m. Eastern time.

Mr. Ferry’s presentation will be webcast live at
http://wsw.com/webcast/ch3/iCAD and on the Investor Relations section of the
Company’s website at www.icadmed.com, where it will also be archived for 90
days following the live presentation.

About The Alpha Select Conference
Entering its fourth year, the Craig-Hallum Alpha Select Conference has earned
a reputation among Craig-Hallum’s clients as an important idea generation
opportunity. Attending companies have been individually selected by the
Craig-Hallum research team and are either currently on the Alpha Select List
or display characteristics that are consistent with the Alpha Select List. The
format of the conference is focused around 1-on-1 meetings with attending
companies preparing an open half hour presentation and spending the remainder
of the day in discussions with individual investors. With an Investor/Company
personnel ratio under 4:1, investors have a high degree of access to company
management.

About iCAD, Inc.
iCAD is a leading provider of advanced image analysis, workflow solutions and
radiation therapies for the early identification and treatment of common
cancers. iCAD offers a comprehensive range of high-performance, upgradeable
CAD solutions for mammography and advanced image analysis and workflow
solutions for Magnetic Resonance Imaging, for breast and prostate cancers and
Computed Tomography for colorectal cancer. iCAD’s Xoft System offers radiation
treatment for early-stage breast cancer that can be administered in the form
of intraoperative radiation therapy or accelerated partial breast irradiation.
The Xoft System is also cleared for the treatment of non-melanoma skin cancer,
cervical cancer and endometrial cancer. For more information, call
877-iCADnow, or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995:
Certain statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to, the
Company’s ability to defend itself in litigation matters, the Company’s
ability to identify a replacement for the Axxent FlexiShield Mini, the risks
relating to the Company’s acquisition of Xoft including, the expected benefits
of the acquisition may not be achieved in a timely manner, or at all; the Xoft
business operations may not be successfully integrated with iCAD’s and iCAD
may be unable to achieve the expected synergies, business and strategic
objectives following the transaction, the risks of uncertainty of patent
protection; the impact of supply and manufacturing constraints or
difficulties; product market acceptance; possible technological obsolescence;
increased competition; customer concentration; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”,
“likely”, and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under
no obligation to provide any updates to any information contained in this
release. For additional disclosure regarding these and other risks faced by
iCAD, please see the disclosure contained in our public filings with the
Securities and Exchange Commission, available on the Investors section of our
website at http://www.icadmed.com and on the SEC’s website at
http://www.sec.gov.

Contact:

For iCAD
Kevin Burns, 937-431-7967
kburns@icadmed.com
or
For iCAD investor relations,
Anne Marie Fields of LHA, 212-838-3777 x6604
afields@lhai.com
or
For iCAD media inquiries
Helen Shik of Schwartz MSL, 781-684-0770
iCAD@schwartzmsl.com
 
Press spacebar to pause and continue. Press esc to stop.